EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease

Jingyuan Ma, Wai Han Yiu, Sydney C W Tang

Diabetic Medicine · 2025

DOI: 10.1111/dme.15427 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetic Medicine, 2025. Verfasst von Jingyuan Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Anaphylatoxins, Complement C5a, Complement Inactivating Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Grants Council of Hong Kong (General Research Fund 17108222), Endowment Fund established at the University of Hong Kong for the Yu Professorship in Nephrology awarded to SCWT, philanthropic donations from Mr. Winston Leung, Mr. K.K. Chan, and Dr. Rita T Liu SBS of L & T Charitable Foundation Ltd. & Bingei Family of Indo Café.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is the most common cause of kidney failure, characterized by chronic inflammation and fibrosis. The complement system is increasingly implicated in the development and progression of diabetic nephropathy. The important complement anaphylatoxins C3a and C5a are key mediators of the innate immune system, which regulates cellular inflammation, oxidative stress, mitochondrial homeostasis and tissue fibrosis. This review summarizes the involvement of anaphylatoxins in the pathogenesis of diabetic kidney disease, highlights their important roles in the pathophysiologic changes of glomerulopathy, tubulointerstitial damage and immune cell infiltration, and discusses the modulatory effects of new anti‐diabetic drugs acting on the complement system. Based on available clinical data and findings from the preclinical studies of complement blockade, anaphylatoxin‐targeted therapeutics may become a promising approach for patients with DKD in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesAnaphylatoxinsComplement C5aComplement Inactivating AgentsComplement C3aHumansAnimalsOxidative Stress

Stichwörter der Autor:innen

anaphylatoxinscomplementdiabetic kidney disease

Substanzen

AnaphylatoxinsComplement C5aComplement Inactivating AgentsComplement C3a

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Förderung

  • Research Grants Council of Hong Kong (General Research Fund 17108222)
  • Endowment Fund established at the University of Hong Kong for the Yu Professorship in Nephrology awarded to SCWT
  • philanthropic donations from Mr. Winston Leung, Mr. K.K. Chan, and Dr. Rita T Liu SBS of L & T Charitable Foundation Ltd. & Bingei Family of Indo Café

Zitieren

APA

Ma, J., Yiu, W. H., & Tang, S. C. W. (2025). Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease. Diabetic Medicine. https://doi.org/10.1111/dme.15427

Vancouver

Ma J, Yiu WH, Tang SCW. Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease. Diabetic Medicine. 2025. doi:10.1111/dme.15427

BibTeX
@article{Ma2025,
  author = {Ma, Jingyuan and Yiu, Wai Han and Tang, Sydney C W},
  title = {Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease},
  journal = {Diabetic Medicine},
  year = {2025},
  doi = {10.1111/dme.15427}
}
Kostenlos starten →